The partners anticipate developing tests that analyze clusters of biomarkers to detect cardiovascular disease, kidney disease, liver cancer, and other diseases.
Glycotest's biomarker test for detection of hepatocellular carcinoma calculates the amount of monosaccharide fucose that appears abnormally on specific serum glycoproteins.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
The researchers used multiple-reaction monitoring mass spec to create a more sensitive assay to AFP-L3, a protein marker for hepatocellular carcinoma.
The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.
A meta-analysis concluded that combining a biomarker blood test with ultrasound increased the detection of early-stage liver cancer by as much as 40 percent.
The device consists of a reservoir that enables the analyte to contact only the top of a screen-printed electrode, increasing sensitivity.